Shuanglan Xu1, Dandan Zhang2, Quan He3, Chenhui Ma4, Sheng Ye5, Linyang Ge6, Liuchao Zhang7, Weihua Liu8, Zi Chen9, Linfu Zhou10. 1. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Nanjing Medical University, Jiangsu 210029, China. Electronic address: xushuanglan99@163.com. 2. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Nanjing Medical University, Jiangsu 210029, China. Electronic address: zhangdd1266@163.com. 3. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Nanjing Medical University, Jiangsu 210029, China. Electronic address: 233586227@qq.com. 4. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Nanjing Medical University, Jiangsu 210029, China. Electronic address: medmch@163.com. 5. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Nanjing Medical University, Jiangsu 210029, China. Electronic address: jonas.yip@benqmedicalcenter.com. 6. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Nanjing Medical University, Jiangsu 210029, China. Electronic address: drleonge@163.com. 7. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Nanjing Medical University, Jiangsu 210029, China. Electronic address: dhxxzlc@outlook.com. 8. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Nanjing Medical University, Jiangsu 210029, China. Electronic address: njmuliuweihua@163.com. 9. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Nanjing Medical University, Jiangsu 210029, China. Electronic address: zi.chen@njmu.edu.cn. 10. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Nanjing Medical University, Jiangsu 210029, China; Institute of Integrative Medicine, Nanjing Medical University, Jiangsu 210029, China. Electronic address: lfzhou@njmu.edu.cn.
Abstract
BACKGROUND: Liuzijue is a traditional Qigong exercise that is commonly performed in China. However, the treatment effects of Liuzijue Qigong are controversial. The aim of this systematic review was to evaluate the efficacy of Liuzijue Qigong in patients with chronic obstructive pulmonary disease (COPD). METHODS: Randomised controlled trials were identified by searching several English and Chinese databases from inception to August 8, 2020. Study selection and data extraction were independently performed by two investigators. Data synthesis and analysis were carried out with Review Manager software 5.2. Quality assessment for each study was based on the modified Jadad scale. RESULTS: Forty studies with 3137 participants were included. Significant improvements were observed in the following outcomes (mean difference, 95% confidence interval): forced expiratory volume in 1 s (0.17, 0.09-0.25) and its percent predicted normal value (6.04, 3.43-8.65), forced expiratory volume in 1 s to forced volume capacity ratio (6.95, 3.06-10.83), 6-min walking distance (33.06, 23.73-42.38), 30-s sit-to-stand test (2.65, 0.98-4.32), COPD assessment test score (- 2.04, - 2.77 to - 1.30), modified Medical Research Council dyspnea scale (- 0.34, - 0.48 to - 0.20), Medical Research Council dyspnea scale (- 0.37, - 0.57 to - 0.18), Traditional Chinese Medicine syndrome score (- 1.85, - 2.86 to - 0.85), Hamilton Anxiety Scale (- 2.31, - 3.04 to - 1.59), Hamilton Depression Scale (- 2.08, - 2.45 to - 1.71) and St. George's Respiratory Questionnaire (- 6.94, - 9.20 to - 4.67). CONCLUSIONS: Liuzijue Qigong may be an effective adjuvant therapy for the improvement of lung function, exercise capacity, health status, mental status and quality of life in patients with COPD.
BACKGROUND: Liuzijue is a traditional Qigong exercise that is commonly performed in China. However, the treatment effects of Liuzijue Qigong are controversial. The aim of this systematic review was to evaluate the efficacy of Liuzijue Qigong in patients with chronic obstructive pulmonary disease (COPD). METHODS: Randomised controlled trials were identified by searching several English and Chinese databases from inception to August 8, 2020. Study selection and data extraction were independently performed by two investigators. Data synthesis and analysis were carried out with Review Manager software 5.2. Quality assessment for each study was based on the modified Jadad scale. RESULTS: Forty studies with 3137 participants were included. Significant improvements were observed in the following outcomes (mean difference, 95% confidence interval): forced expiratory volume in 1 s (0.17, 0.09-0.25) and its percent predicted normal value (6.04, 3.43-8.65), forced expiratory volume in 1 s to forced volume capacity ratio (6.95, 3.06-10.83), 6-min walking distance (33.06, 23.73-42.38), 30-s sit-to-stand test (2.65, 0.98-4.32), COPD assessment test score (- 2.04, - 2.77 to - 1.30), modified Medical Research Council dyspnea scale (- 0.34, - 0.48 to - 0.20), Medical Research Council dyspnea scale (- 0.37, - 0.57 to - 0.18), Traditional Chinese Medicine syndrome score (- 1.85, - 2.86 to - 0.85), Hamilton Anxiety Scale (- 2.31, - 3.04 to - 1.59), Hamilton Depression Scale (- 2.08, - 2.45 to - 1.71) and St. George's Respiratory Questionnaire (- 6.94, - 9.20 to - 4.67). CONCLUSIONS: Liuzijue Qigong may be an effective adjuvant therapy for the improvement of lung function, exercise capacity, health status, mental status and quality of life in patients with COPD.
Authors: Hongshuo Shi; Ting Liu; Chengda Dong; Kun Zhen; Yuxuan Wang; Pengjun Liu; Guomin Si; Lei Wang; Min Wang Journal: Biomed Res Int Date: 2022-08-02 Impact factor: 3.246